• Journal of Ginseng Research
• /
• 제45권2호
• /
• pp.236-245
• /
• 2021

Background: Red ginseng (RG) extract, especially ginsenoside Rg1 and Rb1 fractions has been reported to have antithrombotic activities. However, gastric instability and low intestinal permeability are considered to be obstacles to its oral administration. We hypothesized that stability, permeability, and activities of RG might be improved by encapsulation within nanoparticles (NPs) prepared with antithrombotic coating materials. Methods: RG-loaded chitosan (CS) NPs (PF-NPs) were prepared by complex ionic gelation with the antithrombotic wall materials, polyglutamic acid (PGA), and fucoidan (Fu). The concentrations of PGA (mg/mL, X₁) and Fu (mg/mL, X₂) were optimized for the smallest particle size by response surface methodology. Antithrombotic activities of RG and PF-NPs were analyzed using ex vivo and in vivo antiplatelet activities, in vivo carrageenan-induced mouse tail, and arteriovenous shunt rat thrombosis models. Results: In accordance with a quadratic regression model, the smallest PF-NPs (286 ± 36.6 nm) were fabricated at 0.628 mg/mL PGA and 0.081 mg/mL Fu. The inhibitory activities of RG on ex vivo and in vivo platelet aggregation and thrombosis in in vivo arteriovenous shunt significantly (p < 0.05) increased to approximately 66.82%, 35.42%, and 38.95%, respectively, by encapsulation within PF-NPs. For an in vivo carrageenan-induced mouse tail thrombosis model, though RG had a weaker inhibitory effect, PF-NPs reduced thrombus significantly due to the presence of PGA and Fu. Conclusion: PF-NPs contributed to improve the activities of RG not only by nanoencapsulation but also by antithrombotic coating materials. Therefore, PG-NPs can be suggested as an efficient delivery system for oral administration of RG.

• 한국임상약학회지
• /
• 제34권2호
• /
• pp.79-99
• /
• 2024

Background: There was an important revision of the Korean Clinical Practice Guideline for Stroke (KCPGS) for antithrombotic therapy in patients with acute ischemic stroke in 2022. This review is to provide an updated information in this revision. Methods: The revision history by year after the first announcement was examined for each topic, focusing on antithrombotic therapy during acute phase which was revised in 2022. We compared before and after the revision, and investigated the clinical outcomes presented as evidence. It was also compared with the current U.S. guidelines. Results: The major changes about antiplatelet therapy are a clause stating that dual antiplatelet therapy with clopidogrel and aspirin initiated within 24 hours from the stroke onset and maintained for up to 21-30 days is recommended as an acute treatment, as well as the clause that antithrombotic therapy may be initiated within 24 hours after intravenous thrombolytics and that the use of glycoprotein IIb/IIIa receptor antagonists can be considered in highly selected patients as rescue therapy taking into account of benefit and risk. The change to the use of anticoagulants is that it may be reasonable to start oral anticoagulant between 4 and 14 days after stroke onset for patients with acute ischemic stroke and atrial fibrillation. Conclusions: It will be helpful in improving health outcomes for clinical pharmacists to be aware of the latest information for antithrombotic therapy and to actively use it in pharmaceutical care of stroke patients.

• Archives of Pharmacal Research
• /
• 제10권2호
• /
• pp.115-120
• /
• 1987

Methanol extract of Ilex pubescens roots prolonged bleeding time threefold, and inhibited the generation of malondialdehyde released during platelet aggregation inducted by thrombin. Through several purification procedures, its saponin, named ilexoside, was proved to be responsible for the antithrombotic activities of the plant. Ilexosides A, -D and -J and 24-carboxypomolic acid showed strong inhibitory activities on platelet aggregation induced by thrombin.

• Preventive Nutrition and Food Science
• /
• 제17권1호
• /
• pp.78-82
• /
• 2012

Antithrombotic and fibrinolytic activity of natto was evaluated on platelet aggregation in vitro and in vivo. Natto showed inhibitory effects on platelet aggregation induced by adenosine 5’diphosphate (ADP) and collagen. Orally administered natto also showed fibrinolytic activity in hypercholesterolemia rats. Normal levels of natto, when administered for four weeks, shortened euglobulin clot lysis time (ECLT) and prolonged partial thromboplastin time (PATT) significantly compared to non-treated group. In addition, the natto treatment decreased total cholesterol in serum. These results showed that intake of normal levels of natto can elicit antithrombotic and fibrinolytic effects, suggesting its consumption may improve blood circulation.

• 대한한의학회지
• /
• 제21권4호
• /
• pp.47-54
• /
• 2000

Objectives: The purpose of this study was to investigate the antithrombotic effect of Carthamus tinctorius. Methods: SD rats were used to investigate the inhibitive effect of platelet aggregation (in vitro & in vivo), prothrombin time, platelet count. Mice were used to investigate the survival rate after injection of collagen & epinepbrine. Results: 1. The inhibitive effect of platelet aggregation (in vitro & in vivo) were increased significantly in all groups. 2. Prothrombin time was decreased in both groups. 3. Platelet count was decreased significantly in sample A. 4. Survival rate after injection of collagen & epinepbrine was increased in sample B. Conclusion: According to the above results, it is suggested that Carthamus tinctorius has antithrombotic effects.

• 생약학회지
• /
• 제33권2호통권129호
• /
• pp.120-123
• /
• 2002

The possibility of Galla Rhois(GR) water extract as an antithrombotic agent was investigated. The effect of GR on platelet aggregation in human platelet-rich plasma(PRP) induced by collagen and ADP in vitro and coagulation parameters in a pathological model induced by endotoxin and hydrocortisone acetate(HA) in vivo were examined. In platelet aggregation assay, GR extract significantly inhibited platelet aggregation induced by collagen and ADP in a dose-dependent manner. GR extract significantly increased the number of platelet and shortened prothrombin time(PT) and activated thromboplastin time(APTT) as compared with the control in pathological model induced by endotoxin and HA. Also, GR extract significantly increased fibrinogen level as compared with the control in a pathological model induced HA. These results suggest that GR may be a promising antithrombotic agent.

• 한국식품위생안전성학회지
• /
• 제11권2호
• /
• pp.77-82
• /
• 1996

Green tea catechins(GTC) were studied for its inhibitory effect on human platelet aggregation in vitro, for its antithrombotic effect in mice in viro, and bleeding and clotting time in rats. The catechins were isolated and purified from green tea, which were composed of (-)-epigallocatechin gallate, (-)-epigallocatechin, (-)epicatechin gallate and (-)-epicatechin, GTC produced a potent inhibition of human platelet aggregation in a dose-dependent manner against the stimulants such as ADP, collagen, epinephrine and ristocetin n vitro. GTC also prevented death due to the formation of pulmonary thrombosis by platelet aggregates in mice in a dose-de-pendent manner in viro. GTC increased the bleeding time, whole blood clotting time and plasma clotting time in rats, too. These results suggest that GTC is a promising antithrombotic agent.

• KSBB Journal
• /
• 제27권6호
• /
• pp.375-380
• /
• 2012

We previously reported that Ultra nattokinase$^{(R)}$ showed high fibrinolytic activity and revealed antithrombotic effect in rat blood plasma based on its ability to suppress collagen-induced platelet aggregation. This research was carried out to verify the clot lysing activity and blood flow enhancing effects of Ultra nattokinase$^{(R)}$ via monitoring and comparing the antithrombotic effects in rat artery between oral administration of Ultra nattokinase$^{(R)}$ and maltodextrin. SD rats were fed with 1.11 mg/kg of Ultra nattokinase$^{(R)}$ for 4 weeks. The effect on arterial thrombosis was then evaluated using an antithrombotic model after induction by $FeCl_3$. Detected fibrinolytic activity was proportional to the content of Ultra nattokinase$^{(R)}$ and statistical extents of the antithrombotic activity was enhanced strongly twice rather than control group. The PT and the aPTT, however, showed only a small difference between two groups. The results suggest that Ultra nattokinase$^{(R)}$ can effectively treat thromboembolism and enhance blood flow, and that Ultra nattokinase$^{(R)}$ can also prevent venous occlusion by aiding clot lysis.

• 한국환경과학회지
• /
• 제28권7호
• /
• pp.639-643
• /
• 2019

We aimed to evaluate antithrombotic efficacy of Protaetia brevitarsis extract during 21 days. Rats (SPF rat, weight 240~260 g) were divided into 16 groups (5 rats per group), they were: control group and Protaetia brevitarsis extract groups with dose of 0.1, 0.5, 1, 2.5, 5, 10, 25, 50, 75, 100, 200, 250, 500, 750, 1,000 mg/kg kg of body weight. Thromboplastin time (PT) and activated partial thromboplastin time (aPPT) as antithrombotic efficacy were tested in this animal experiment (at 7, 14 and 21 days). Overall, the admistration dose of Protaetia brevitarsis extract over 50 mg/kg at 7, 14 and 21 days for PT and over 25 mg/kg at 7, 14 and 21 days for aPPT tented to be longer than that of other groups. In addition, the optimal admistration doses of Protaetia brevitarsis extract to improves antithrombotic efficacy were 75, 100, 200 and 250 mg/kg at 7, 14 and 21 days for PT (p<0.05) and 50 and 100 mg/kg at 7 days, 75 mg/kg at 14 days, or 50, 100, 200 and 250 mg/kg at 21 days for aPPT (p<0.05). It can be concluded that Protaetia brevitarsis extract at optimal levels have antithrombotic efficacy.

• 한국환경성돌연변이발암원학회:학술대회논문집
• /
• 한국환경성돌연변이발암원학회 2002년도 Current Trends in Toxicological Sciences
• /
• pp.118-118
• /
• 2002